Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Kane Biotech Inc
V.KNE
Alternate Symbol(s):
KNBIF
Healthcare
Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired...
from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:KNE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(8)
•••
KevinOleary
X
View Profile
View Bullboard History
Comment by
KevinOleary
on Jun 29, 2024 5:48pm
RE:RE:RE:New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global
The timelines for dispersin trials are determined 100% by the FDA. kne just tried to estimate when the trials would start, but it's a mug's game. The FDA is a massive bureaucracy, and doesn
...more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 27, 2024 9:57am
RE:RE:New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global
Yup, and, for once, they've met their promises in regards to timing so, this is refreshing and very encouraging for the future. GLTA
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 27, 2024 9:17am
RE:New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global
The news we were waiting for...on-time...excellent! Now we can start looking at sales increase over time, new Revyve products intorduction, new distribution partnership for Europe, Australia, etc
...more
(201)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 27, 2024 9:16am
RE:New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global
at one minute to midnight, finally the full production.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2024 8:30am
New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global
Kane Also Signs Long-Term Manufacturing Agreement With Halo Pharma WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product...
read article.
(201)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 26, 2024 9:38am
RE:RE:RE:June 25th - insider transaction
I guess we'll know soon enough, only 2 days left.
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 26, 2024 9:19am
RE:RE:June 25th - insider transaction
The first Revyve commercial shipment will be big for this company but I don't know if it's material news at this point since it's been mentioned many times by the company that product
...more
(201)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 26, 2024 6:10am
RE:June 25th - insider transaction
Good to see but at the same time that make me wonder if we'll have a news about Revyve production. Usually insiders are in a blackout before any material news...
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Jun 25, 2024 10:37pm
June 25th - insider transaction
Interesting...see link below...an insider bought a 'few' shares today; Mr. Edwards shares purchase GLTA
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 25, 2024 10:32pm
RE:RE:RE:Latest DispersinB news from this week (and last)
Yup, I need to dig a little more but I think that DispersinB is already considered safe and I-Med will only add it to their product lines and get the FDA to approve the new formula. KNE is trying to
...more
(201)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 25, 2024 4:19pm
RE:RE:Latest DispersinB news from this week (and last)
Someone on CEO answered the same question and it make sense https://ceo.ca/kne?fa89a80c871f
(201)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 25, 2024 12:22pm
RE:Latest DispersinB news from this week (and last)
How can they have a deal for something that is not approved and will most likely take several years to have approval ?
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Jun 25, 2024 9:53am
Latest DispersinB news from this week (and last)
Surprising licensing deal for DispersinB was announced earlier today...see link below; I-Med Pharma licensing deal announcement On a less positive note, the DispersinB phase 1 trial was postponed
...more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 13, 2024 12:56pm
RE:RE:RE:Apart from traveling
100% agree with your comment about KNE typically not meeting deadlines...deadlines that they are setting themself...I think that they should be using a more conservative approach when mentioning
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >